Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Shares Outstanding (Diluted Average) (2023 - 2025)

Historic Shares Outstanding (Diluted Average) for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $82.9 million.

  • Monte Rosa Therapeutics' Shares Outstanding (Diluted Average) rose 113.53% to $82.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.9 million, marking a year-over-year increase of 113.53%. This contributed to the annual value of $73.9 million for FY2024, which is 4380.23% up from last year.
  • According to the latest figures from Q3 2025, Monte Rosa Therapeutics' Shares Outstanding (Diluted Average) is $82.9 million, which was up 113.53% from $82.9 million recorded in Q2 2025.
  • Over the past 5 years, Monte Rosa Therapeutics' Shares Outstanding (Diluted Average) peaked at $83.0 million during Q1 2025, and registered a low of $49.3 million during Q1 2023.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $71.2 million (2024), whereas its average is $66.9 million.
  • In the last 5 years, Monte Rosa Therapeutics' Shares Outstanding (Diluted Average) surged by 6463.28% in 2024 and then skyrocketed by 113.53% in 2025.
  • Quarter analysis of 3 years shows Monte Rosa Therapeutics' Shares Outstanding (Diluted Average) stood at $51.4 million in 2023, then soared by 43.8% to $73.9 million in 2024, then grew by 12.22% to $82.9 million in 2025.
  • Its last three reported values are $82.9 million in Q3 2025, $82.9 million for Q2 2025, and $83.0 million during Q1 2025.